Microbot Medical Inc.
Close on Oct 19, 2026
- Market cap
- $63.99M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2017 Ended Jun 30, 2017 | Aug 15, 2017 | After market close | – | – | – |
| Q1 FY2017 Ended Mar 31, 2017 | May 15, 2017 | Before market open | – | – | – |
| Q4 FY2015 Ended Dec 31, 2015 | Mar 23, 2016 | After market close | – | – | – |
| Q3 FY2015 Ended Sep 30, 2015 | Nov 2, 2015 | After market close | – | – | – |
| Q2 FY2015 Ended Jun 30, 2015 | Aug 6, 2015 | After market close | – | – | – |
| Q1 FY2015 Ended Mar 31, 2015 | May 5, 2015 | After market close | – | – | – |
| Q4 FY2014 Ended Dec 31, 2014 | Mar 16, 2015 | After market close | – | – | – |
| Q3 FY2014 Ended Sep 30, 2014 | Nov 6, 2014 | After market close | – | – | – |
| Q2 FY2014 Ended Jun 30, 2014 | Aug 12, 2014 | After market close | – | – | – |
| Q1 FY2014 Ended Mar 31, 2014 | May 14, 2014 | After market close | – | – | – |
| Q4 FY2013 Ended Dec 31, 2013 | Mar 12, 2014 | After market close | – | – | – |
| Q3 FY2013 Ended Sep 30, 2013 | Nov 5, 2013 | After market close | – | – | – |
Press releases
Announcements Microbot Medical filed with the SEC
Medical ® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® Reports Over 100% Revenue and Customer Growth
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical ® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® Announces a Notable Health System as the First in Michigan to
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
to Hold Conference Call to Review Recent Progress; Executive Team to be Joined by Current LIBERTY Users, Dr. Charles Briggs
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
LIBERTY ® Endovascular Robotic System is Now Adopted by Multiple Accounts
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY ®
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® Commences Full Market Release (FMR) of the LIBERTY ® Endovascular Robotic System in the U.S. at
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical ® ’s
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® Strengthens LIBERTY® Endovascular Robotic System Position with Publication of its ACCESS PVI Pivotal
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® to Participate at the 38th Annual Roth Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
Medical ® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical® Aligns with Recently Adopted Policy of the Largest U.S.-Based Medical Association to Expand Protection for Healthcare Professionals
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event
Regulation FD disclosure · EX-99.1 to Form 8-K
General Hospital is the First Health System in Florida to Adopt the LIBERTY ® Endovascular Robotic System
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® ’s LIBERTY ® Endovascular Robotic System Continues to Expand Market Visibility; Being Featured
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® ’s LIBERTY ® Endovascular Robotic System Highlighted at a Leading Vascular Disease Management
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® to Leverage Current Users Experience of the LIBERTY ® Endovascular Robotic System at Key Oncology
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
Other events · EX-99.1 to Form 8-K
Announces Emory University Hospital as the First Hospital in the World to Adopt the New LIBERTY ®
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical® Commences the Limited Market Release of its LIBERTY® Endovascular Robotic System in the U.S.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical ® to Commercially Debut the LIBERTY ® System at The Symposium on Clinical Interventional Oncology
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical ® Secures U.S. Based Logistics Partner to Support the Commercialization of Its LIBERTY® Endovascular
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Medical ® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Medical ® CEO to Discuss Recent FDA Clearance of the LIBERTY ® Endovascular Robotic System
Regulation FD disclosure · EX-99.1 to Form 8-K
Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K